Cemiplimab combined with chemotherapy chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis
Objective: Cemiplimab combined with chemotherapy has emerged as a promising treatment option for advanced non-small cell lung cancer (NSCLC). Accordingly, this study has been conducted to evaluate the cost-effectiveness of this combination therapy in comparison to chemotherapy alone from the perspec...
| Published in: | Therapeutic Advances in Medical Oncology |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-11-01
|
| Online Access: | https://doi.org/10.1177/17588359231213619 |